RadNet, Inc.

NasdaqGM RDNT

RadNet, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 30.42%

RadNet, Inc. Gross Profit Margin is 30.42% for the Trailing 12 Months (TTM) ending September 30, 2024, a 126.87% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

RadNet, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 13.41%, a 15.67% change year over year.
RadNet, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 11.59%, a -22.89% change year over year.
RadNet, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 15.03%, a 58.57% change year over year.
RadNet, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 9.48%, a -20.95% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: RDNT

RadNet, Inc.

CEO	Dr. Howard G. Berger M.D.
IPO Date	Jan. 3, 1997
Location	United States
Headquarters	1508, 1510 and 1516 Cotner Avenue
Employees	10,000
Sector	Health Care
Industries Hospitals & Clinics Medical Instruments

Description

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Key trends

Past 5 years